Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Post-marketing surveillance to gather information regarding the tolerance and efficacy of
Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.